ISTH 2023 | Albutrepenonacog alfa in Japanese patients with hemophilia B
Azusa Nagao
• 27 Jun 2023
Azusa Nagao, MD, Ogikubo Hospital, Tokyo, Japan, discusses her recent publication on the real-world use of albutrepenonacog alfa (rFIX-FP), an albumin fusion gene recombinant factor IX (FIX), in Japanese patients with hemophilia B. Dr Nagao shares a case study of a patient with mild hemophilia B who benefited from prophylaxis using albutrepenonacog alfa in a clinical setting. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
